- SPANNR
- Posts
- Issue #27
Issue #27
Issue #27
November 17, 2022 | Issue #27
Good Evening
. Welcome back to another issue of Spannr.
Thanksgiving is next week, which means you won't be hearing from us until the week after, on December 1st. And because we're all here to live longer, be sure to not eat too much (caloric restriction!), don't drink any alcohol, wear blue light blockers if you're watching football or the parade... and don't forget to exercise the morning after. 🙂
Jokes aside – Happy Turkey Break.
Relax, embrace those around you, show your thanks, and enjoy the days off!
In this week's newsletter
:
🔒 Rapid reactions to FDA's NMN ban
💰 Funding news from this past week
📢 Business news + weekend reading material
FDA Restricts NMN Sales: The Implications, Winners & Losers, & Other Rapid Reactions
One of the longevity community’s most discussed supplements, nicotinamide mononucleotide or NMN, received a major blow from the FDA this week.According to the regulator, NMN may no longer be marketed or sold as a “dietary supplement” in the US. With an estimated market to be worth $280.2 million in 2022 alone, the ruling the FDA’s decision has left many in the space searching for answers.Why is the FDA doing this? And why now, years after NMN became widely available?Well, this is where it gets interesting…
Jnana Therapeutics, a biotech company leveraging its chemoproteomics platform to discover medicines for challenging-to-drug targets, raises $107 Million Series C from Bain Capital Life Sciences with participation from RA Capital Management, Polaris Partners, Versant Ventures, Avalon Ventures & Pfizer Ventures
Nymbl Science, a digital balance trainer, raises $12 Million Series B from Cobalt Ventures Outcomes, Collective Growth Capital, and 450 Ventures
Casma Therapeutics, a biotech company focused on reprogramming autophagy to treat disease, raises $46 Million Series C from Amgen Ventures, Astellas, Eisai, Euclidean Capital, Mirae Asset, and Ono Venture Investment, with participation from Eventide Asset Management, Schroders Capital, The Column Group, and Third Rock Ventures
Bonum Therapeutics, a biopharmaceutical company using allosteric regulation to create conditionally active and less toxic medicines, raises $93 Million Series A from Rivervest Venture Partners, Roche Venture Fund, Digitalis Ventures, 3x5 Partners, Codon Capital, & Vivo Capital.
Fifty Years Launches ‘Fast Grants’ For Female Reproductive Science To Close The Gender Research Gap
Mogling Bio entering Licensing Agreement with Cincinnati Children’s Hospital Medical Center
BioViva Science to Begin Series A Raise in 2023
FOXO Technologies Announces Agreement With Haven Life
Stagnant Scientific Productivity Holding Back Growth (WSJ)
The Biggest Company in the World (a16z)
Does the Peer Review Process Need Blockchain? (NEO.LIFE)
The human race at 8 billion (Axios)
Inside the billion-dollar meeting for the mega-rich who want to live forever (MIT Technology Review)
Quantum Healthy Longevity for healthy people, planet, and growth (The Lancet)
What can blockchain do for increasing human longevity? (CoinTelegraph)
Healthspan versus lifespan: new medicines to close the gap (Nature; Aging)
Performance:
Latest Price: $125.037d-Return: -0.19%Market Cap: $10.66b
Big Movers: